Physician profile
Mackenzie C Boyer
NPI 1598400129
$2,076.99
in general payments reported to CMS, 2019-2025
24 companies · $598 in 2025
The $598 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $799 · 2024: $563 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.41 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $364.33 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $363.01 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $325.80 | 2023-2025 | |
| Astellas Pharma US INC | $251.91 | 2023-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $146.68 | 2023-2025 | Jardiance, Mounjaro, Emgality |
| Organon LLC | $92.30 | 2023-2025 | Nexplanon |
| Novo Nordisk INC | $74.82 | 2023-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $64.09 | 2023-2024 | Cologuard Collection Kit |
| Biotronik INC. | $55.50 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.02 | 2023-2024 | Xifaxan |
| Teleflex LLC | $44.08 | 2022-2023 | Turnpike |
| Merck Sharp & Dohme LLC | $32.19 | 2023-2025 | M-M-R II, Gardasil 9, Proquad |
| Medtronic, INC. | $21.97 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.79 | 2025 | Trintellix |
| Seqirus USA INC | $20.75 | 2025 | Flucelvax, Fluad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.54 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $18.84 | 2023 | |
| Xeris Pharmaceuticals, INC. | $18.70 | 2023 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $18.16 | 2023 | |
| Axsome Therapeutics, INC. | $17.85 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $16.14 | 2024 | |
| Amgen INC. | $15.42 | 2024 | Otezla, Repatha |
| Terumo Medical Corporation | $14.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.78 | 2023 | Jardiance, Tradjenta, Synjardy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.